Her2 negative luminal breast carcinoma and Ki-67 evaluation.

@article{Pavlakis2012Her2NL,
  title={Her2 negative luminal breast carcinoma and Ki-67 evaluation.},
  author={Kitty Pavlakis and Thomas Vrekoussis and Anna Tsipoura and Artemis Tsenga and Petroula Arapantoni-Dadioti and Theofani V Gavresea and Irini Messini and Vassilis Barbounis},
  journal={Breast},
  year={2012},
  volume={21 4},
  pages={529-33}
}
AIM To determine the degree of inter-observer variability in defining the percentage of Ki-67 immunohistochemical expression in breast carcinoma cases and to investigate the validity of using the cut-point of 14% for the administration of adjuvant treatment in luminal B (Her2 negative) carcinomas. MATERIALS AND METHODS 99 ER, PR positive, Her2 negative breast carcinomas were consecutively selected from the Pathology files of "IASO" Women's Hospital. Ki-67 immunostaining was evaluated by four… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Ki-67 labeling index is associated with recurrence after segmentectomy under video-assisted thoracoscopic surgery in stage I non-small cell lung cancer.

Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia • 2011

Ki-67 quantitative evaluation as a marker of cervical intraepithelial neoplasia and human papillomavirus infection.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society • 2010

Similar Papers

Loading similar papers…